Travere Therapeutics, Inc.

NASDAQ:TVTX

Biotechnology

Healthcare
$50.24 +1.20%

+$0.65 today

Market cap
$4.82B
Beta
1.14
P/E (TTM)
-235.0
EPS (TTM)
-$0.23
52W Low $13.97High $55.99

Volume 0.84M

Average 2.31M

TVTX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Travere Therapeutics, Inc.NASDAQ: TVTX

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows in line with its trailing trend

Q3 FY2026 weighted avg shares of 94.63M shares rose 6.0% year over year, in line with the +5.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +6.0% holds above the trailing-twelve-month pace of +5.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
94.63M+1.2% QoQ
Last fiscal yearDec 2025
89.21M+13.1% YoY
LTMSep 2026
92.57M+5.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.0%——
1 year+13.1%——
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
89.21M USD
Year-over-year change
+13.1%
4-year CAGR
+10.5%

Weighted Avg Shares vs competitors

How TVTX compares with its peers on the latest reported figures

  • TVTX's LTM Sep 2026 weighted avg shares of 92.57M shares is the 2nd highest of the 5 companies compared; the peer median is 73.62M shares.
  • Its year-over-year change of +5.9% is the 4th highest of 5, against a peer median of +12.3%.
  • Over three fiscal years its annual growth of +11.8% compares with a peer median of +14.5%.
TVTX Competitors Peer median
Weighted Avg Shares for TVTX and competitors
Company Period LTM YoY 3-year CAGR
PROKProKidney Corp.LTM Mar 2026135.66M +18.2%+29.6%
TVTXTravere Therapeutics, Inc.LTM Sep 202692.57M +5.9%+11.8%
MLYSMineralys Therapeutics, Inc.LTM Jun 202679.68M +45.9%+135.7%
PHARPharming Group N.V.LTM Mar 202667.56M -5.0%-4.8%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
Peer median (excluding TVTX) 73.62M+12.3%+14.5%

Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue131.84M109.46M145.24M233.18M490.73M
Cost of Revenue3.82M4.42M11.45M7.74M10.34M
Gross Profit128.02M105.04M133.79M225.43M480.39M
Gross Margin97.1%96.0%92.1%96.7%97.9%
Research & Development201.16M227.33M244.99M282.7M206.01M
Selling, General & Admin126.28M197.52M265.54M264.12M337.2M
Operating Expenses327.44M424.85M521.93M549.26M543.21M
Depreciation & Amortization12.75M20.72M38.53M43.56M60.74M
EBITDA(184.46M)(299.42M)(326.25M)(265.77M)22.22M
EBITDA Margin-139.9%-273.5%-224.6%-114.0%4.5%
Operating Income(199.43M)(319.81M)(388.14M)(323.83M)(62.82M)
Operating Margin-151.3%-292.2%-267.2%-138.9%-12.8%
Interest Income1.99M6.28M21.77M17.82M12.72M
Interest Expense19.68M11.01M11.33M11.18M10.75M
Other Income / Expenses(17.46M)(11.34M)12.03M3.32M13.55M
Income Before Tax(216.88M)(331.16M)(376.11M)(320.51M)(49.27M)
Pre-Tax Margin-164.5%-302.5%-259.0%-137.5%-10.0%
Income Tax Expense409K313K223K120K988K
Net Income(180.09M)(278.48M)(111.4M)(321.55M)(25.55M)
Net Margin-136.6%-254.4%-76.7%-137.9%-5.2%
EPS (Basic)(3.01)(4.37)(1.50)(4.08)(0.56)
EPS (Diluted)(3.01)(4.37)(1.50)(4.08)(0.56)
Weighted Avg Shares59.83M63.76M74.27M78.89M89.21M
Weighted Avg Shares (Diluted)59.83M63.76M74.27M78.89M89.21M

Travere Therapeutics, Inc.

NASDAQ:TVTX

Intrinsic Alpha fair value

Locked

Current Price

$50.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.